newsfilter
← Latest News
ClinicalTrials.gov·

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease - NCT04540497

Time to disease flare, defined as the time in days from Day 1 (dosing) to the date of the first treated and Adjudication Committee-determined IgG4 RD flare within the 52-week RCP.